Pharmaceutical company Sunshine Biopharma’s HMEC study has indicated the non-toxicity of anticancer compound Adva-27a to healthy tissue at high concentrations.
According to the data, concentrations of up to 24 micromolar of Adva-27a did not measurably inhibit the normal growth process of these cells.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Sunshine Biopharma CEO Dr Steve Slilaty said the data indicates the non-toxicity of Adva-27a to healthy tissue.
"This further confirms that Adva-27a will have great utility for cancer therapy in humans, particularly in view of the fact that twenty-four micromolar is over three times the actual concentration estimated to ultimately be used in patient therapy," Slilaty said.
The company completed several new IND-Enabling studies, including one in which the cytotoxic activity of Adva-27a was measured in the HMEC cell line.
HMEC are non-cancerous human mammary epithelial cells isolated from reduction mammoplasty tissu,e and HMEC is the standard cell line used for ascertain the molecular and biochemical basis for in-vitro toxicity of drug candidates.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAdva-27a has previously established efficacy at killing different types of multidrug resistant cancer cell lines, such as MES-SA/Dx5, a Uterine Sarcoma cell line, MCF-7/MDR, a breast cancer cell line and H69AR, a small-cell lung cancer cell line.
